FDA D.I.S.C.O. Burst Edition: FDA approves Rylaze (asparaginase erwinia chrysanthemi (recombinant...

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

Medical Device Quality Management System Regulation Design and Development

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

Public Meeting: Reauthorization of the Biosimilar User Fee Act

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Celebrates 120 Years

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

2025 FDA Achievements

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory...